METiS TECHBIO-P's stock plummeted 5.15% during intraday trading on Friday, continuing a sustained retreat from its post-IPO highs.

The decline reflects multiple challenges facing the company, which remains in early commercialization stages with approximately RMB 1.5 billion in accumulated losses over the past three years and volatile revenue streams creating uncertainty about its growth outlook. Additionally, some internationally placed shares carry no lock-up period, generating persistent profit-taking pressure as early investors exit positions.

Despite recent strategic developments including the launch of its AiProtein platform and a strategic alliance with Deerfield to co-develop next-generation in vivo protein therapeutics and immunotherapies, market enthusiasm has cooled rapidly following the company's initial public offering, sustaining downward pressure on the share price.